Abstract: The invention relates to a liquid recovery system for a motor vehicle where such a recovery system includes at least one liquid intake that communicates with a tank, which is designed to store liquid from the liquid intake, and is designed with an arrangement below the motor vehicle's beltline.

Abstract: A water-based composition in a form suitable for topical administration contains a vasoconstrictor and is in the form of an emulsion having liquid crystals. The vasoconstrictor is chosen from the group consisting of brimonidine or salts thereof, in a solvent-based phase. The solvent-based phase includes polyethylene glycol in combination with propylene glycol, a hydrophilic film-forming agent chosen from a polyvinylpyrrolidone/vinyl acetate copolymer, and polyvinylpyrrolidone in a non-crosslinked, crosslinked or acetate form, taken alone or in combination, glycerine, an emulsifier chosen from (i) the combination of PEG-75 stearate and glyceryl monostearate, and (ii) the combination of polyoxyethylene-20 sorbitan monosteearate (polysorbate-60) and cetostearyl alcohol, an oleic acid or an oleyl alcohol, and an oil phase suitable for obtaining the emulsion having liquid crystals.

Abstract: Compositions in a form suitable for topical administration, which is water-based, contain a vasoconstrictor. The vasoconstrictor is chosen from brimonidine or salts thereof, in a solvent-based phase of polyethylene glycol in combination with propylene glycol and/or dimethyl sulfoxide (DMSO), a hydrophilic film-forming agent chosen from a polyvinylpyrrolidone/vinyl acetate copolymer, polyvinylpyrrolidone in a non-crosslinked, crosslinked or acetate form, taken alone or in combination, and glycerine which is in the form of a hydrogel. Methods for prevention and/or treatment of dermatitis resulting from radiation, notably in the context of a radiotherapy treatmen, involve administering the compositions to a patient in need thereof.

Abstract: A speech-processing system may provide access to one or more virtual assistants via an audio-controlled device. A multi-agent component of a device may be used to coordinate control of device process(es) regardless of the invoked agent and without necessarily sharing information between agents and corresponding speech-processing system(s). Device-state information may be sent from the multi-agent component to a speech-processing system to interpret a user command. If the command relates to a device process control it may be routed to a device skill and to the multi-agent component of the device. The multi-agent component may track a device state and may inform a particular speech-processing system if a process related to the particular speech-processing system has been controlled.

Abstract: A mesh for an atomizer assembly is provided, including a first surface, a second surface, and a plurality of nozzles extending between the first surface and the second surface, the first surface being at least partially coated with a hydrophilic coating or the second surface being at least partially coated with a hydrophobic coating, the plurality of nozzles defining an inner surface, and the inner surface being at least partially coated with the hydrophilic coating. An atomizer assembly for an aerosol-generating device, and an aerosol-generating device comprising an atomizer assembly, are also provided.

Abstract: The invention provides CARs (CARs) that specifically bind to BCMA (B-Cell Maturation Antigen). The invention further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making such CARs, engineered immune cells, and nucleic acids. The invention further relates to therapeutic methods for use of these CARs and engineered immune cells for the treatment of a condition associated with malignant cells expressing BCMA (e.g., cancer).

Abstract: The nacelle can have an inlet portion having a duct wall and an outer skin, the duct wall being annular around an axis and having a surface forming a radially-outer delimitation to a gas path upstream of a fan area, the duct wall extending from a rounded inlet edge of the nacelle to the fan area, a cavity located inside the inlet portion, a compressed air inlet leading into the cavity, and an outlet fluidly connecting the cavity to the gas path, the outlet having a plurality of apertures disposed circumferentially around the duct wall, the apertures sloping circumferentially.

Abstract: A user may access multiple virtual assistants via a voice-enabled device. The device may receive a command from the user, detect a wakeword corresponding to one of the assistants, and send audio data to a command processing system corresponding to the selected assistant. The device transmits encrypted audio data to one or more systems and, upon detecting a wakeword or wake command corresponding to one of the systems, the device may provide an encryption key to that particular system. The system may decrypt and process the audio data without additional latency introduced by having to wait for the audio data to arrive.

Abstract: The invention relates to formulations comprising a halogenated salicylanilide, or a pharmaceutically acceptable salt thereof, and a cyclodextrin. The formulations may be in the form of a liquid formulation, particularly an aqueous formulation, and provide high concentrations of solubilised halogenated salicylanilide. Also disclosed a formulations in the form of powders and aerosols. Also disclosed are the formulations for use in the treatment of bacterial and viral infections, and the treatment of inflammatory diseases. The formulations are particularly suitable for administration by inhalation for the treatment of bacterial and viral pulmonary infections and the treatment of pulmonary inflammatory diseases.

Abstract: An aircraft divan includes a lateral bracket connecting between front and rear legs with lateral bracket front and rear ends, a first track defined by the lateral bracket between the lateral bracket front and rear ends, an upright, having upright top and bottom ends, a second track defined by the upright between the upright top and bottom ends, a seat pan having seat pan front and rear ends, the seat pan being slidingly connected to the first track adjacent to the seat pan rear end, and a backrest having backrest top and bottom ends, the backrest being slidingly connected to the second track adjacent to the backrest top end. The seat pan rear end is pivotably connected to the backrest adjacent to the backrest bottom end such that movement of the seat pan is transmitted to the backrest so as to move together between upright and berth positions.

Abstract: Inhalable compositions comprising niclosamide, or a pharmaceutically acceptable salt thereof, and polyethylene glycol; aerosols of the compositions; and the pulmonary administrations for use in the treatment of viral infections, for example respiratory viral infections.

Abstract: Methods and systems for operating an engine are provided. An engine core temperature is monitored. When the engine core temperature is below an engine thermal limit adjusted for a level of deterioration of the engine, an output power of the engine is set in accordance with a reference power based on non-thermal limits of the engine. When the engine core temperature is near or above the engine thermal limit adjusted for the level of deterioration of the engine, the output power of the engine is set to a value lower than the reference power based on non-thermal limits of the engine to reduce the engine core temperature.

Abstract: Methods and systems for operating an engine are provided. An engine core temperature is monitored. When the engine core temperature is below an engine thermal limit adjusted for a level of deterioration of the engine, an output power of the engine is set in accordance with a reference power based on non-thermal limits of the engine. When the engine core temperature is near or above the engine thermal limit adjusted for the level of deterioration of the engine, the output power of the engine is set to a value lower than the reference power based on non-thermal limits of the engine to reduce the engine core temperature.

Abstract: The invention is directed to compounds of formula (I), and salts thereof. The compounds are inhibitors of kinase activity, in particular PI3-kinase activity.

Abstract: The invention is directed to compounds of formula (I), and salts thereof. The compounds are inhibitors of kinase activity, in particular PI3-kinase activity.

Abstract: The present invention relates to a method of preventing or reducing dermatological side effects of the therapeutic agents in a subject without substantial loss in efficacy, where the therapeutic agents would otherwise have significant effects. In particular, this beneficial effect is achieved by using an alpha-2 adrenergic agonist to isolate body areas from pharmacological effects of the therapeutic agents, such as a chemotherapeutic agent, and to prevent or reduce inflammatory processes.

Abstract: A substrate coated with a non-stick fluoropolymer coating is provided, the coating having excellent abrasion and scratch resistance. The coating contains: i.) a continuous primer layer adhered to the substrate containing a polymer binder, a first fluoropolymer and first inorganic film hardner particles, ii.) a discontinuous midcoat layer containing aggregate particles adhered to the primer layer and distributed discontinuously across the surface of the primer layer so as to reveal exposed areas of the surface of the primer layer, wherein a portion of the aggregate particles are in clusters, and wherein the aggregate particles contain second fluoropolymer and second inorganic film hardner particles, and iii.) a topcoat layer containing a third fluoropolymer adhered to the midcoat layer and the exposed areas of the surface of the primer layer at points where there is no midcoat layer.

Abstract: The invention relates to a method of treating a viral infection caused by or associated with SARS-CoV-2 in a subject, the method comprising administering to the subject by inhalation intraorally and/or intranasally a therapeutically effective amount of a formulation comprising niclosamide, or a pharmaceutically acceptable salt thereof, and a cyclodextrin.

Abstract: A mobile projection device for projection mapping, the device comprising a road vehicle having a structure mounted on wheels, and at least one light projector unit mounted on the structure and configured to be controlled so as to provide projection mapping in the environment outside the mobile projection device.

Abstract: A method of preventing or reducing dermatological side effects of the therapeutic agents in a subject without substantial loss in efficacy, where the therapeutic agents would otherwise have significant effects, is described. In particular, the beneficial effects are achieved by using an alpha-2 adrenergic agonist to isolate body areas from pharmacological effects of the therapeutic agents, such as a chemotherapeutic agent, and to prevent or reduce inflammatory processes.